BRIEF-Bayer seeks EU approval for regorafenib for use against GIST
FRANKFURT, Sept 5
FRANKFURT, Sept 5 (Reuters) - Bayer AG : * Says regorafenib (Stivarga) submitted for European marketing authorization
for the treatment of gastrointestinal stromal tumors (GIST).
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video